A review synthesizes clinical trial and real-world evidence on how sequential CAR-T therapies can counter antigen escape and product exhaustion in relapsed hematological malignancies. The paper frames escape as a recurring mechanism that undermines durability and positions sequential infusions and multimodal integration as potential response-building strategies. Rather than single-agent durability, the analysis emphasizes how treatment sequencing and combinations may preserve target engagement across evolving tumor phenotypes. The review also highlights how antigen loss and cellular exhaustion can emerge under selective pressure. For clinicians and product teams, the work supports ongoing interest in optimizing CAR-T retreatment schedules and engineering or selection approaches to improve long-term disease control.